Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12619000436178
Ethics application status
Approved
Date submitted
12/03/2019
Date registered
18/03/2019
Date last updated
22/04/2020
Date data sharing statement initially provided
18/03/2019
Date results provided
22/04/2020
Type of registration
Retrospectively registered

Titles & IDs
Public title
Impact of Ubiquinol Supplementation on Endothelial Function in Subjects at Risk of Cardiovascular Disease Development
Scientific title
Impact of Ubiquinol Supplementation on Endothelial Function in Subjects at Risk of Cardiovascular Disease Development: a Double Blind, Randomized, Placebo–controlled, Parallel Groups, Spontaneous Clinical Study
Secondary ID [1] 297685 0
Nil known
Universal Trial Number (UTN)
U1111-1229-8941
Trial acronym
QHHC-FMD-PILOT
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Dyslipidemia 311992 0
Endothelial Dysfunction 311993 0
Condition category
Condition code
Cardiovascular 310557 310557 0 0
Diseases of the vasculature and circulation including the lymphatic system
Metabolic and Endocrine 310558 310558 0 0
Metabolic disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
The study aims to evaluate the impact of a supplementation with ubiquinol (reduced form of ubiquinone or reduced CoQ10) on endothelial function and oxidative stress in patients with mild to moderate dyslipidemia.
During Screening Visit the eligibility criteria will be verified and, if fulfilled, each subject will be randomized to one of the 3 study groups after signing the Informed Consent Form.
At Screening Visit and at Week 4, subjects will receive the assigned test product, according to randomization, for consumption at home during the coming 4 weeks and leave the facility.
The study products include test treatment (ubiquinol, two dosages, 100 and 200 mg daily) and placebo; details on these study products are given in the study products dossiers. Each product (ubiquinol or placebo), have to be taken daily at breakfast and dinner (total two pills: 1 before breakfast and 1 before dinner).
The active study products, Ubiquinol-QH 100 mg, will be provided in the form of softgel capsules. Each active softgel capsule contains ubiquinol (Kaneka QHâ„¢ active antioxidant form of coenzyme Q10) 100 mg. The product contains also soy and other ingredients: medium chain triglycerides, gelatin, glycerin, ascorbyl palmitate, purified water, beeswax, soy lecithin, annatto extract.
Placebo will consist of softgel capsules too, matching the active study products but without any active principle.

The subjects will consume 2 softgel capsules per day according to the following scheme:
- Group A - Ubiquinol 200mg/day: 2 Ubiquinol-QH 100 mg soft capsules/day
- Group B - Ubiquinol 100mg/day: 1 Ubiquinol-QH 100 mg soft capsule and 1 Placebo capsule /day
- Group C – Matched placebo: 2 Placebo capsules/day

The study products, provided as softgel capsules, will be consumed at home by the subjects, one capsule in the morning and one capsule in the evening, with a meal. Subjects will be instructed to complete a daily diary, in order to evaluate the compliance to both treatment and dietary restrictions. Diary and unopened and empty study products packs will be returned on each follow-up visit and checked by the study personnel as an assessment of compliance.

During each visit a short physical examination will be performed and a blood sample (approximately 10 ml) will be collected from the vein in the left arm to evaluate CoQ10 levels and the secondary endpoints. After acclimatisation and rest for at least 30 minutes blood pressure (triplicate, first discarded) and flow-mediated dilation (FMD) (baseline or Week 4 and 8 measurement) will be measured.
Intervention code [1] 313928 0
Treatment: Other
Comparator / control treatment
Placebo capsules, equal in colour, shape and weight to study products capsules (softgel capsules) but without active ingredients.
Control group
Placebo

Outcomes
Primary outcome [1] 319416 0
Change in endothelium-dependent vasodilation at week 8, assessed through non-invasive ultrasound measurement of the flow-mediated dilation (FMD) of the brachial artery. Measures will be conducted by a trained sonographer using a dedicated ultrasound machine and analysed through an edge-detection and wall-tracking software developed by Quipu (Pisa, Italy).
Timepoint [1] 319416 0
Visit 2 (8 weeks)
Secondary outcome [1] 368074 0
Change in endothelium-dependent vasodilation at week 4, assessed through non-invasive ultrasound measurement of the flow-mediated dilation (FMD) of the brachial artery. Measures will be conducted by a trained sonographer using a dedicated ultrasound machine and analysed through an edge-detection and wall-tracking software developed by Quipu (Pisa, Italy).
Timepoint [1] 368074 0
Visit 1 (4 weeks)
Secondary outcome [2] 368075 0
Change in the ratio between oxidized and total Coenzyme Q10 (CoQ10) plasma levels (composite outcome). Oxidized and total CoQ10 levels will be measured by high-pressure liquid chromatography (HPLC) using a direct extraction method.
Timepoint [2] 368075 0
Visit 1 (4 weeks), Visit 2 (8 weeks)
Secondary outcome [3] 368076 0
Evaluation of plasma levels of nitric oxide quantified in terms of its stable reaction product (nitrites and nitrates) through the Griess reaction.
Timepoint [3] 368076 0
Visit 1 (4 weeks), Visit 2 (8 weeks)
Secondary outcome [4] 368077 0
Evaluation of plasma levels of peroxinitrite (evaluation of oxidative inactivation of NO to peroxinitrite using fluorescent probes).
Timepoint [4] 368077 0
Visit 1 (4 weeks), Visit 2 (8 weeks)
Secondary outcome [5] 368078 0
Evaluation of susceptibility to oxidation of plasma lipoprotein quantified as kinetic of conjugate dienes formation following copper exposure.
Timepoint [5] 368078 0
Visit 1 (4 weeks), Visit 2 (8 weeks)

Eligibility
Key inclusion criteria
This study will include male and post-menopausal female subjects.
- Male aged 35 - 65 years (35 and 65 included).
- Post-menopausal female (without a period for more than 1 year), until 65 years (65 included).
- Subjects enrolled for primary prevention but never treated (only life style modification suggested, according guidelines).
- FMD level measured between 2,5% and 6% (at Screening Visit).
- Body mass index (BMI) between 18.5 and 29.9 kg/m2.
- LDL Cholesterol levels between 130 and 200 mg/dl (based on previous evaluation, performed within 1 month from the Screening Visit).
Minimum age
35 Years
Maximum age
65 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
A subject will not be eligible for inclusion in this study if any of the following apply:
- Use of any cardiovascular disease related drugs prior to Screening Visit.
- Participation in any clinical trial while participating in this trial.
- Greater than 5% change in body weight within 1 month of Screening Visit.
- Subjects playing competitive physical activity.
- Subject taking lipid-altering drug therapy within four weeks prior to Screening Visit. Also excluded are supplements known to have significant lipid altering effects, such as niacin (>100 mg per day), garlic (> 600 mg per day), omega-3 fatty acids (> 1 g omega-3 fatty acids per day), red yeast rice extract, phytostanols / phytosterols (> 0.5 g per day), soluble fiber (>1 g per day), chitosan (> 1 g per day) and conjugated linoleic acid (CLA; > 3 g per day).
- Subject taking any concomitant treatment with phosphodiesterase inhibitors (e.g. sildenafil citrate, tadalafil, vardenafil) and donors of NO (nitric oxide), like other long-acting derivatives of GTN (glyceryl trinitrate), such as isosorbide dinitrate and amyl or butyl nitrite.
- Excluded concurrent medications are: systemic corticosteroids (nasal and inhaled corticosteroids are permitted), orlistat, bile acid resins, no more than 1 g of prescription omega-3 fatty acids, cyclical or non-continuous hormone therapy (estrogen or testosterone).
- No more than 2 alcoholic units per day. Units are defined as 12 grams of ethanol, e.g. a small glass (125 ml) of medium gradation wine, a can of beer (330 ml) of average gradation or 40 ml dose of liquors.
- Consumption of flavonoids-enriched products.
- Consumption of vitamin C-enriched products or supplements containing vitamin C.
- Has a diagnosis of type 1 or type 2 diabetes mellitus, hepatic or renal impairment or diseases, thyroid disorders.
- Known cardiovascular disease or stroke, except for conditions that are deemed clinically insignificant by Principle Investigator or Sub-investigator, or study site physician (e.g. clinically insignificant atherosclerotic lesions observed by imaging studies).
- History of significant gastrointestinal disease such as severe constipation, diarrhea, malabsorptive disease, inflammatory bowel disease (e.g. Crohn’s disease, ulcerative colitis).
- History of severe psychiatric illness which in the opinion of the investigator would interfere with the optimal participation in the study.
- History if cancer within 5 years of Screening Visit (except for successfully treated basal and squamous cell carcinoma of the skin).
- Known HIV seropositivity.
- History of bariatric surgery.
- Allergic to the test products or placebo.
- Smokers > 10 cigarettes/day.
- Individuals who in the opinion of the principal investigator have a risk of non-compliance to the study procedures or who are otherwise not appropriate to include in this clinical trial.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation is concealed. Subjects fulfilling inclusion criteria will be randomly allocated to one of the 3 study groups; treatments will be randomised to subject numbers (1-51).
A Pharmacy designate independent of the study will conduct the product dispensing procedure. Each subject will receive two bottles containing either Ubiquinol 100 mg or Placebo. The product is dispensed according to a 3-digit code previously assigned by a 3rd party to each bottle. The link between the treatment code and the treatment will not be available to the personnel involved in the collection, revision, or evaluation of adverse events, to the clinical laboratory, or to personnel who could have an impact on the outcome of the study, until after the end of the study (when all adverse events have been finalized).
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
A simple randomization technique, i.e. a randomization based on a single sequence of random assignments, will be used. A computer-generated random numbers list will be used and subjects will be assigned a number according to their order of inclusion in the study.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
Sample size calculation was carried out with using G*power Software.
The parameters used to compute sample size for this study were retrieved from the paper by Gao et al., 2012 (DOI: 10.1016/j.atherosclerosis.2011.10.027), who performed a meta-analysis of 5 randomized controlled trials.
Mean and SD from the article by Watts GF et al., 2002 (DOI: 10.1007/s00125-001-0760-y), one of the randomized controlled trials mentioned in the reference article (see Fig. 2 in Gao et al.), were considered as appropriate values to be taken into account: considering group one FMD mean (SD) as 1.6 (1.16) and second group FMD mean (SD) as -0.4 (2.24), with 80% power and 5% two-sided significance level, 14 subjects per group are required.
In this study, considering a 20% dropout rate, a total of 52.5 subjects should have been enrolled; a sample size equal to 51 subjects was deemed as appropriate.
It is to be noted that in this study the minimum increment of FMD reached with the number of patients provided for each group is to be considered as equal to 1.6% (according to Figure 2 shown in Gao et al., in particular by referring to the study of Watts, which provides a sample size similar to ours).

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
Actual
19/12/2016
Date of last participant enrolment
Anticipated
Actual
25/04/2017
Date of last data collection
Anticipated
Actual
26/06/2017
Sample size
Target
51
Accrual to date
Final
51
Recruitment outside Australia
Country [1] 21341 0
Italy
State/province [1] 21341 0

Funding & Sponsors
Funding source category [1] 302211 0
Hospital
Name [1] 302211 0
I.N.R.C.A. (Italian National Research Centre on Aging)-IRCCS
Country [1] 302211 0
Italy
Primary sponsor type
Hospital
Name
I.N.R.C.A. (Italian National Research Centre on Aging)-IRCCS
Address
Via della Montagnola, 81
60127 Ancona (AN)
Italy
Country
Italy
Secondary sponsor category [1] 302059 0
None
Name [1] 302059 0
Address [1] 302059 0
Country [1] 302059 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 302890 0
Comitato Etico Regione Marche - Ethics Committee of the Marche Region
Ethics committee address [1] 302890 0
Ethics committee country [1] 302890 0
Italy
Date submitted for ethics approval [1] 302890 0
19/07/2016
Approval date [1] 302890 0
15/12/2016
Ethics approval number [1] 302890 0
2016-0614 IN

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 91750 0
Dr Roberto Antonicelli
Address 91750 0
Department of Cardiology
I.N.R.C.A. (Italian National Research Centre on Aging)-IRCCS
Via della Montagnola, 81
60127 Ancona (AN)
Italy
Country 91750 0
Italy
Phone 91750 0
+390718003450
Fax 91750 0
Email 91750 0
r.antonicelli@inrca.it
Contact person for public queries
Name 91751 0
Jacopo Sabbatinelli
Address 91751 0
Department of Clinical and Molecular Sciences
Università Politecnica delle Marche
Via Tronto, 10/A
60126 Ancona (AN)
Italy
Country 91751 0
Italy
Phone 91751 0
+390712205243
Fax 91751 0
Email 91751 0
j.sabbatinelli@pm.univpm.it
Contact person for scientific queries
Name 91752 0
Luca Tiano
Address 91752 0
Department of Environmental and Life Sciences
Università Politecnica delle Marche
Via Ranieri, 65
60131 Ancona (AN)
Italy
Country 91752 0
Italy
Phone 91752 0
+390712204394
Fax 91752 0
Email 91752 0
l.tiano@univpm.it

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

Doc. No.TypeCitationLinkEmailOther DetailsAttachment
1575Informed consent form    377173-(Uploaded-12-03-2019-02-14-54)-Study-related document.pdf
1610Ethical approval    377173-(Uploaded-12-03-2019-20-50-03)-Study-related document.pdf
4025Study protocol    377173-(Uploaded-09-08-2019-23-53-07)-Study-related document.pdf



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
EmbaseUbiquinol ameliorates endothelial dysfunction in subjects with mild-to-moderate dyslipidemia: A randomized clinical trial.2020https://dx.doi.org/10.3390/nu12041098
N.B. These documents automatically identified may not have been verified by the study sponsor.